ECSP099029A - Nuevos análogos del péptido intestinal vasoactivo - Google Patents

Nuevos análogos del péptido intestinal vasoactivo

Info

Publication number
ECSP099029A
ECSP099029A EC2009009029A ECSP099029A ECSP099029A EC SP099029 A ECSP099029 A EC SP099029A EC 2009009029 A EC2009009029 A EC 2009009029A EC SP099029 A ECSP099029 A EC SP099029A EC SP099029 A ECSP099029 A EC SP099029A
Authority
EC
Ecuador
Prior art keywords
vasoactive intestinal
intestinal peptide
new analogs
analogs
new
Prior art date
Application number
EC2009009029A
Other languages
English (en)
Inventor
Wajiha Khan
David Robert Bolin
Hanspeter Michel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38786842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099029(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP099029A publication Critical patent/ECSP099029A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un agonista del receptor VPAC-2 de fórmula [X-(Id. De Sec. Nº: 2)-Y] para el tratamiento de las enfermedades obstructivas pulmonares, por ejemplo la EPOC, administrado, por ejemplo, por inhalación.
EC2009009029A 2006-07-06 2009-01-05 Nuevos análogos del péptido intestinal vasoactivo ECSP099029A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81880506P 2006-07-06 2006-07-06

Publications (1)

Publication Number Publication Date
ECSP099029A true ECSP099029A (es) 2009-02-27

Family

ID=38786842

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009029A ECSP099029A (es) 2006-07-06 2009-01-05 Nuevos análogos del péptido intestinal vasoactivo

Country Status (20)

Country Link
US (1) US20080096807A1 (es)
EP (1) EP2041168A2 (es)
JP (1) JP2009542593A (es)
KR (1) KR20090027239A (es)
CN (1) CN101484468A (es)
AR (1) AR061825A1 (es)
AU (1) AU2007271274A1 (es)
BR (1) BRPI0714306A2 (es)
CA (1) CA2656757A1 (es)
CL (1) CL2007001956A1 (es)
CR (1) CR10518A (es)
EC (1) ECSP099029A (es)
IL (1) IL196122A0 (es)
MA (1) MA30590B1 (es)
MX (1) MX2009000013A (es)
NO (1) NO20090027L (es)
PE (1) PE20081000A1 (es)
RU (1) RU2009103811A (es)
TW (1) TW200819139A (es)
WO (1) WO2008003612A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5827218B2 (ja) 2010-04-30 2015-12-02 株式会社三和化学研究所 生理活性物質等の生体内安定性向上のためのペプチド及び生体内安定性が向上した生理活性物質
CN102827268B (zh) * 2011-06-13 2016-08-24 中肽生化有限公司 新型血管肠肽类似物及其制备方法和用途
US8866872B2 (en) 2011-06-21 2014-10-21 Mitel Networks Corporation Conferencing and collaboration system and methods thereof
WO2014145718A2 (en) * 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US11052132B2 (en) * 2014-05-08 2021-07-06 Phasebio Pharmaceuticals, Inc. Methods and compositions for treating cystic fibrosis
ITUB20159175A1 (it) * 2015-12-23 2017-06-23 Materie Plastiche Pisane S R L Composizione polimerica antibatterica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3879371A (en) * 1971-09-17 1975-04-22 Sami I Said Isolation of vasoactive intestinal peptide
GB8427651D0 (en) * 1984-11-01 1984-12-05 Beecham Group Plc Compounds
GB8525852D0 (en) * 1985-10-19 1985-11-20 Beecham Group Plc Compounds
JPS62246595A (ja) * 1986-04-17 1987-10-27 Eisai Co Ltd 気菅支拡張作用・降圧作用ペプタイド
US4835252A (en) * 1987-02-26 1989-05-30 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
AU656230B2 (en) * 1991-10-11 1995-01-27 F. Hoffmann-La Roche Ag Cyclic vasoactive peptides
WO1997029126A1 (en) * 1996-02-09 1997-08-14 F. Hoffmann-La Roche Ag Synthesis of vip analog
US20050203009A1 (en) * 2004-03-12 2005-09-15 Bayer Pharmaceuticals Corporation VPAC1 selective antagonists and their pharmacological methods of use
CA2577326A1 (en) * 2004-08-18 2006-03-02 Eli Lilly & Company Selective vpac2 receptor peptide agonists
MX2007004116A (es) * 2004-10-08 2007-10-05 Forbes Medi Tech Res Inc Composiciones farmaceuticas de polipeptidos intestinales vasoactivos.

Also Published As

Publication number Publication date
MX2009000013A (es) 2009-01-23
CA2656757A1 (en) 2008-01-10
JP2009542593A (ja) 2009-12-03
US20080096807A1 (en) 2008-04-24
BRPI0714306A2 (pt) 2014-05-20
KR20090027239A (ko) 2009-03-16
AU2007271274A1 (en) 2008-01-10
EP2041168A2 (en) 2009-04-01
RU2009103811A (ru) 2010-08-20
PE20081000A1 (es) 2008-08-06
AR061825A1 (es) 2008-09-24
CN101484468A (zh) 2009-07-15
IL196122A0 (en) 2011-08-01
CL2007001956A1 (es) 2008-04-18
TW200819139A (en) 2008-05-01
NO20090027L (no) 2009-01-15
WO2008003612A3 (en) 2008-02-28
WO2008003612A2 (en) 2008-01-10
CR10518A (es) 2009-01-27
MA30590B1 (fr) 2009-07-01

Similar Documents

Publication Publication Date Title
SA521431209B1 (ar) مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
ECSP099029A (es) Nuevos análogos del péptido intestinal vasoactivo
CY1121543T1 (el) Ενωση πυριδυλαμινοοξεικου οξεος
PE20220938A1 (es) Compuestos agonistas de gipr
EA201000157A1 (ru) Неосновные антагонисты рецептора меланин-концентрирующего гормона 1 типа и их применение
CY1121853T1 (el) Συνδυαστικη θεραπεια για την αγωγη του διαβητη
MX359516B (es) Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.
MX2009012967A (es) Polipeptidos, dominios variables de anticuerpo y antagonistas.
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
MA33818B1 (fr) Nouveaux antagonistes du récepteur ccr2 et leurs utilisations
CL2012001722A1 (es) Compuestos derivados de 3-hidroxi-5-arilisotiazol, agonistas del receptor 40 acoplado a la proteina g (gpr40); composición farmacéutica que los comprende; y método para el tratamiento o la prevención de la diabetes.
MX2010003949A (es) N-fenil-bipirrolidina carboxamidas sustituidas y uso terapeutico de las mismas.
WO2007028633A3 (en) Treatment of diabetes related obesity
MX2012003389A (es) Moduladores de gpr40 de pirrolidina.
MX2010003948A (es) N-fenil-birrolidin ureas sustituidas y uso terapeutico de las mismas.
CO6361991A2 (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos.
WO2010149578A3 (en) Novel biphenyl and phenyl-pyridine amides
EA025158B9 (ru) Гетероциклические соединения, лекарственные средства, содержащие указанные соединения, их применение и способы их получения
ATE525394T1 (de) Peptide mit verbesserten eigenschaften mit der biologischen wirkung eines vasoaktiven intestinalen peptids (vip) und ihre verwendung zur behandlung von lungenerkrankung
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
PH12021551243A1 (en) Oxyntomodulin peptide analog formulations
MX2010004003A (es) N-fenil-pirrolidinilmetlipirrolidin amidas sustituidas y uso terapeutico de las mismas.
NO20080552L (no) GLP-1 farmasoytiske sammensetninger
CO6361996A2 (es) 5- (2-{ [6- (2, 2-difluoro-2-feniletoxi) hexil] amino} -1-hidroxietil) -8-hidroxiquinolin-2 (ih)-ona y su uso en el tratamiento de enfermedades pulmonares
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.